Tag Archives: Gilead Sciences Inc.

Top Stories for Week of May 18, 2020

COVID-19 cases slacken in US, but as more states reopen, the future is shaky. More than two-thirds of US states have lifted or relaxed restrictions on business and public life… Read more »

Top Stories for Week of May 11, 2020

Quarrel flares up between White House and the CDC over reopening guidelines. The Centers for Disease Control and Prevention has repeatedly found its suggestions for fighting the coronavirus outbreak taking… Read more »

Top Stories for Week of May 4, 2020

Trump’s Warp-Speed Plan aims to produce COVID-19 vaccine this year. US President Donald Trump said on Thursday (April 30, 2020) the US plans to accelerate the development of a coronavirus… Read more »

Top Stories for Week of April 20, 2020

Trump gives governors 3-step plan to revive economy soon; many experts doubt it will happen. The White House is encouraging states to begin opening back up and lifting social-distancing measures… Read more »

Top Stories for Week of March 9, 2020

      No Comments on Top Stories for Week of March 9, 2020

COVID-19 Addenda: Trump signs $8.3 billion emergency spending package; Italy coronavirus deaths near 200; $2 billion needed to develop new vaccine; U of Washington has closed classrooms. President Donald Trump… Read more »

Top Stories for Week of March 2, 2020

As the situation worsens, Gilead begins two, late-stage studies to test drug for coronavirus. The coronavirus, or COVID-19, has infected more than 80,000 people in about three dozen countries since… Read more »

Why Galapagos’s Phase 3 rheumatoid arthritis success is largely irrelevant.

The News: Galapagos NV (Mechelen BEL) and Gilead Sciences Inc. (Foster City CA) have reported positive results from a Phase 3 trial testing Galapagos’s lead drug candidate in patients with… Read more »

ViiV Healthcare’s success with monthly combo HIV med making Gilead sweat over its HIV franchise. After World Cup fiasco, England chasing California in $$$$/rep race.

The News: GlaxoSmithKline PLC’s (London) ViiV Healthcare unit now has results to support a two-drug monthly injection co-developed with Johnson & Johnson (New Brunswick NJ) as it pushes ahead with its ambition… Read more »

With a frenzy of popping corks and champagne toasts, Sangamo bags French biotech TxCell as Europe’s CAR T-cell science expanding into autoimmune disease. SGMA is a buy.

The News: Sangamo Therapeutics Inc. (Richmond CA) has acquired TxCell SA (Valbonne FRA) with a view toward utilizing its chimeric antigen receptor (CAR) technology to prevent organ transplant rejections and treat… Read more »

Kite snags deal with Dutch biotech Gadeta to advance brand new CAR T-cell treatment for solid tumors.

The News: Kite Pharma Inc. (El Segundo CA) reportedly will support Gadeta BV (Utrecht NLD) in the development of a new type of CAR T-cell therapy that could be more… Read more »